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1,25-dihydroxyvitamin DBecause of the increasing trend of body contour enhancements with injections, implants, and ﬁllers, clinicians
should be on high alert for the possibility of silicone-induced hypercalcemia as one of the differential diagnoses
in a patient with history of silicone use. Hypercalcemia as a result of silicone injections has been reported, and
there is concern that there will be more cases given the popularity of cosmetic silicone. Cases involved a mother
and daughter (70 & 55 years) who presented in 2013 with hypercalcemia after cosmetic silicone injections in
2007. Evaluation showed 1, 25-dihydroxyvitamin D-mediated hypercalcemia and progressive renal dysfunction;
lymph node biopsy showed granulomatous silicone lymphadenitis. MRI of the pelvis revealed abnormal signal
enhancement within the subcutaneous gluteal adipose tissue and enlarged inguinal lymph nodes. For persistent
hypercalcemia and hypercalciuria, surgical resection of siliconematerial and granulomas is a successful approach
to normalize the serum calcium level.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hypercalcemia as a result of silicone injections has been reported,
and there is concern that there will be more cases as the popularity of
cosmetic silicone grows. We report two cases (mother and daughter)
of silicone-induced hypercalcemia that resolved after surgical removal
of granulomatous tissue.2. Case 1
A 50-year-old Latina woman was referred to University of Texas
MD Anderson Cancer Center for evaluation of hypercalcemia. This
patient had received 3 injections of ‘silicone’-like material in each
gluteal region for cosmetic purposes in 2007 from an unlicensed
individual. Between 2010–2013 she developed inguinal lymphadenop-
athy, induration over the injection area, fatigue, polyuria, intermittent
confusion, weight gain, tingling and numbness and hair loss. In 2013
she was found to have a corrected serum calcium of 16.7 mg/dL (8.4–
10.2 mg/dL), 1,25-dihydroxyvitamin D of 71 pg/mL (18–78 pg/mL),ternal Medicine, University of
lvd, Unit # 1465, Houston, TX
ards).
. This is an open access article underintact parathyroid hormone level of 5 pg/mL (9–80 pg/mL), an unde-
tectable parathyroid hormone-related protein and angiotensin
converting enzyme (ACE) level of 96 U/L (8–53 U/L). She was hospital-
ized, hydrated, treated with corticosteroids (prednisolone 20 mg) and
referred for evaluation.
The patient developed nephrolithiasis in 2007 andhad ureteral stent
placement in 2012. She had frequent urinary tract infections, migraine
headaches, depression, anxiety, arthritis, and hypothyroidism. Physical
examination revealed an anxious female; abdominal examination was
remarkable for abdominoplasty and ﬁrm palpable bilateral inguinal
lymph nodes. There was hyperpigmentation and induration over the
buttocks consistent with post-inﬂammatory hyperpigmentation and ﬁ-
brosis due to silicone injection. Numerous ﬁrm nodules were palpated
in the gluteal area bilaterally. Laboratory testing revealed serum calcium
of 10.24 mg/dL (Table 1) and serum creatinine of 1.7 mg/dL (eGFR 44
mL/min/1.73 m2) (0.6–1.00 mg/dL; 80–120 mL/min/1.73 m2). Pelvic
MRI revealed abnormal signal enhancement within the subcutaneous
adipose tissue over the gluteal region and enlarged lymph nodes. The
largest node in the right inguinal region was 1.5 × 1.8 × 2.2 cm; biopsy
of a right inguinal lymph node showed granulomatous silicone lymph-
adenitis. Histologic sections of the lymph node showed diffuse involve-
ment by non-necrotizing granulomatous inﬂammation with numerous
variably sized vacuoles and foreign-body giant cells. In addition to the
vacuoles, scattered round, pigmented, foreign material-containingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Laboratory results for case 1 and case 2 with corresponding reference levels.
Test Case 1 Case 2 References
Pre-presentation
Oct 2013
Post-presentation
Oct 2014
Pre-presentation
Oct 2013
Post-presentation
Oct 2014
Serum calcium (mg/dL) 17.3 10.2 11.5 9.6 8.4–10.2
Parathyroid hormone (pg/mL) 5 16 b3.0 22 9–80
25-OH vitamin D (ng/mL) 28 39 24 20 30–100
1,25-OH vitamin D (pg/mL) 71 69 89 65 18–78
Serum phosphate (mg/dL) 3.5 3.6 3.5 3.8 2.5–4.5
CTX beta Crosslaps (pg/mL) 244 574 274 865 40–840
Serum creatinine (mg/dL) 1.4 0.66 1.3 0.99 0.6–1.00
Angiotensin converting enzyme (U/L) 96 37 65 26 8–53
Glomerular ﬁltration rate (mL/min) 40 95 40 55 80–120
Luteinizing hormone (mIU/mL) 62.2 1.0–11.4
Postmenopausal
7.7–58.5
Estradiol, S (pg/mL) b12.0 Postmenopausal b55
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derson, the patient had Cushingoid features and requested cessation
of corticosteroids; she was subsequently treated with pentoxiphylline
(400mg two times a day). Pentoxiphylline is a competitive nonselective
phosphodiesterase inhibitor that raises intracellular ATP, activates
protein kinase A, and inhibits TNF α and leukotriene synthesis, thereby
reducing inﬂammation. The patient tolerated pentoxiphylline.
Over the next 2 months, she showed signs of persistent hypercalce-
mia. The patient resumed corticosteroids and pentoxiphylline was in-
creased (400 mg four times a day). Serum calcium level remained in
the high normal range (Fig. 1) without improvement of renal function.
Suboptimal response to medical therapy resulted in a decision for
surgical intervention. She underwent sharp excisional debridement of
the granulomatous tissue in her buttocks and 90% of the granulomatous
tissuewas successfully resected. Serumcalcium, 1,25-dihydroxyvitamin
D, intact PTH and renal function normalized (Table 1).
3. Case 2
The mother received one ‘silicone’ injection in each gluteal region in
2007, from the same unlicensed individual. Co-morbidities included
nephrolithiasis (2010), diabetes mellitus, Hashimoto's thyroiditis, andFig. 1. Serum calcium level and interventiGERD. In 2012, the patient presented with fatigue, abdominal bloating,
diarrhea, urinary tract infections, cold intolerance, polydipsia, and
polyuria. Serum calcium was 13 mg% (8.4–10.2 mg/dL). She received
similar treatment with corticosteroids and was subsequently referred
to MD Anderson Cancer Center for further management.
She appeared as a well-nourished Latina patient. Induration and hy-
perpigmentation were noted in the gluteal region with inguinal lymph
node enlargement. Serum calcium was 9.74 mg/dL, ACE level of 60 U/L
(8–53 U/L) and 1,25-dihydroxyvitamin D level was 106 pg/mL (18–78
pg/mL); intact parathyroid hormone was 23 pg/mL (9–80 pg/mL).
Consider factors such as age and potential effect on renal function
as well as comorbidity of diabetes mellitus, case 2 was not consid-
ered for aggressive medical management that was initially
attempted for case 1. After her daughter's successful surgical resec-
tion of granulomatous material, the patient underwent sharp exci-
sional debridement of the granulomatous tissue. Delayed healing of
surgical incision was evident.
4. Discussion
We report that surgical excision of granulomatous tissue leads
to resolution of silicone induced hypercalcemia. A large number ofons at various time points for Case 1.
Fig. 2. a: T1-weighted 1.5 Tesla MR Examination of the pelvis at time of diagnosis shows
extensive deposition of silicone in gluteal subcutaneous tissue bilaterally. b: Similar MR
examination of the pelvis about 6 months following resection of the inﬁltrated silicone
shows minimal residual deposit.
165B.J. Edwards et al. / Bone Reports 5 (2016) 163–167substances, such as parafﬁn, petrolatum, vegetable oils, liquid petro-
latum, hydrous wool fat, sesame oil, and beeswax have been used for
cosmetic purposes. However, when introduced into the body, these
produce foreign-body granulomas (e.g., oleoma, parafﬁnoma, or
lipogranuloma) (Winer et al., 1964). Injectable silicone has been
used extensively over the last 40 years for soft tissue augmentation
(Schwartzfarb et al., 2008). Silicones are long-chained polymers of
dimethylsiloxane and may be liquid, resin, or solid depending on
the length of their polymeric chain (Winer et al., 1964). The most
common of these silicone polymers, medical ﬂuid 360, is a clear, col-
orless ﬂuid characterized by properties such as chemical inertness,
high hydrophobicity, low volatility, resistance to decomposition by
heat, and low surface tension (Braley, 1973). Although considered
biologically inert, this material has been implicated in a variety of
adverse reactions, including granulomas, disﬁguring nodules, and lymph-
edema,with latent periods ranging fromweeks to decades (Schwartzfarb
et al., 2008; Bigata et al., 2001; Chasan, 2007; Rapaport et al., 1996). For
these reasons, it is generally recommended that silicone injections be
performed only by trained physicians using medical-grade silicone
(Bigata et al., 2001).
There have been 6 reports of hypercalcemia secondary to silicone in-
jections for cosmetic purposes (Agrawal et al., 2013; Kozeny et al., 1984;
Loke and Leow, 2005; Schanz et al., 2012; Camuzard et al., 2013; Visnyei
et al., 2014). Silicone spallation from the roller-pump insert in dialysis
blood lines that led to accumulation of silicone and granuloma forma-
tion was seen in 2 dialysis patients (Altmann et al., 1987). Persistent
hypercalcemia in these 2 cases eventually resolved after replacement
with silicone-free blood lines (Altmann et al., 1987). Hypercalcemia
with increased levels of plasma calcitriol (1-25-dihydroxyvitamin D3)
is commonly seen in granulomatous diseases such as sarcoidosis, tuber-
culosis, leprosy, and fungal infections (Lafferty, 1991). The pathogenesis
of granuloma formation in response to silicone particles is unclear. It is
believed to occur under the regulatory inﬂuence of cytokines produced
by localmononuclear phagocytes, T cells, dendritic cells, ﬁbroblasts, and
other local cells. The activation of these cells is triggered by adulterants
added to silicone to enhance ﬁbroplasia or denature host proteins
adsorbed to the silicone. Fibrinogen that adsorbs to silicone surfaces
undergoes a conformational change that causes it to display two previ-
ously hidden epitopes. These epitopes can induce an inﬂammatory
response leading to the inﬂux of neutrophils and macrophages (Desai
et al., 2006).
The conversion of calcidiol to calcitriol occurs via a 1-α hydroxylase
in the kidney proximal tubule and is stimulated by PTH. In granuloma-
tous diseases, activated mononuclear cells (particularly macrophages)
produce calcitriol from calcidiol independent of PTH signaling, stimulat-
ing increased gastrointestinal calcium absorption and hypercalcemia
and hypercalciuria (Sharma, 2000). Parathyroid hormone is normally
suppressed as seen in our two patients. Hypercalcemia in silicone
granulomas has also been attributed to accelerated prostaglandin pro-
duction. The macrophages in the granulomas are loaded with silicone
particles, which stimulate arachidonic acid metabolism that results
in prostaglandin synthesis (Bommer et al., 1984). Typical of 1,25
dihydroxyvitaminD3-mediated hypercalcemia,we noted the correction
of hypercalcemia and normalization of serum calcitriol levels caused by
short-term administration of glucocorticoids. We therefore concluded
that the source of hypercalcemia and elevated calcitriol levels in our
patient was extra-renal as none of the recognized stimulators of
renal vitamin D3 conversion (PTH, sex steroids, elevated calcidiol, or
hypophosphatemia) (DeLuca, 1978) were present in this patient with
renal insufﬁciency. Another interesting feature of these two cases is
the apparent dose–response relationship between the number of injec-
tions the patients had and the severity of the hypercalcemia. It is unclear
whether this is coincidental or has pathophysiologic signiﬁcance. Un-
treated or chronic hypercalcemia can have a deleterious effect on
renal function, lead to acute kidney injury, nephrolithiasis — as was
seen in these cases (Auron et al., 2009; Schulze, 1982). Resolution ofhypercalcemia in case 1 resulted in recovery of renal function. Laborato-
ry results have also shown the bone resorption marker serum CTX
increase markedly in both cases following surgical resection. Bone
resorption marker serum CTX is physiologically elevated during child-
hood, growth, and fracture and trauma healing. Many diseases, such
as hyperparathyroidism, hypercalcemia of malignancy, and bone me-
tastases, can result in accelerated andunbalanced bone turnover. Unbal-
anced bone turnover is also found in age-related and postmenopausal
osteopenia and osteoporosis (Christgau et al., 2000; Garnero et al.,
2001). These could possibly explain the elevated bone resorptionmark-
er serum CTX in our cases.
A granulomatous reaction in case 1 was identiﬁed with a regional
lymph node biopsy, which is similar to the ﬁndings of earlier case re-
ports (Agrawal et al., 2013; Kozeny et al., 1984; Schanz et al., 2012;
Camuzard et al., 2013; Desai et al., 2006).Most of these caseswere treat-
ed with corticosteroids and ethanercept, but in none of these cases is
there long-term follow-up data. Ethanercept reduces cytokine levels
by selectively binding to TNF-α and preventing it from associating
with its cell surface receptor. The dilemmawe faced in these patients
was profound hypercalcemia and signiﬁcant side-effects of cortico-
steroids — a problematic combination. While there was concern
about the potential for surgical complications from this procedure,
it was the combination of the hypercalcemia and severe local soft tis-
sue manifestations with no prospect for elimination of the silicone
166 B.J. Edwards et al. / Bone Reports 5 (2016) 163–167material that led to a decision for surgical intervention. To the best of
our knowledge, these cases describe the ﬁrst examples of the use of
this approach to treat a serious medical problem. MR examinations
of the pelvis shows minimized residual deposit comparing 6 months
following resection and at time of diagnosis (Fig. 2a and b). Both pa-
tients have been followed for more than one year and have not had
recurrence of their hypercalcemia. We recognize, however, that the
debridement was not complete and there is potential for recurrence,
as the serum calcium values have declined to the upper normal limit.5. Conclusion
Because of the increasing trend of body contour enhancements with
injections, implants, and ﬁllers using silicone, clinicians should be on
high alert of the possibility of silicone-induced hypercalcemia as one
of the differential diagnoses in a patient with history of silicone use.
For persistent hypercalcemia and hypercalciuria, surgical resection of
silicone material and granulomas is a successful approach to normalize
the serum calcium level.Conﬂicts of interest
None.Acknowledgement
Elizabeth Grubbs, M.D. for performance of lymph node biopsy.Appendix AFig. 1. Granuloma formation. A: Numerous vacuoles in the lymph node, imparting a Swiss ch
B:Higher power view of the Psammoma bodies. C: Brown colored foreign bodies. D:Non-caseat
plasma cells and small lymphocytes. Hematoxylin and eosin stain, 200× (A), 400× B, C, D.References
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